Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.
about
Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapyGene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses.Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialTransferring a synthetic gene circuit from yeast to mammalian cells.Hypoxic response elements and Tet-On advanced double-controlled systems regulate hVEGF 165 and angiopoietin-1 gene expression in vitroSafety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelRelease of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaOncolytic-adenovirus-expressed RNA interference for cancer therapy.Par-4 as a potential target for cancer therapy.Single vector non-leaky gene expression system for Drosophila melanogaster.A computational analysis of pro-angiogenic therapies for peripheral artery disease.
P2860
Q33386030-4CA10DD3-0154-45A4-B3F3-2FAE4FAAC1ABQ33828114-39C1ECDE-F629-4DBC-AB09-FA6AF6CC7279Q34022048-60E98778-B030-4912-B55D-BED8C800C7D0Q35999648-81FE5D08-41A1-42FE-8A74-04B2B4219D19Q36422224-03C4E384-B438-45BF-8D01-FB5D6EE822EFQ36534329-172D78C1-82BB-496F-A9C3-F7E7DD4E0B78Q36614050-9E49613D-EF39-4607-8B7E-B3100C8ABEB9Q36683198-247462DA-EC72-4B1F-8A42-D293DC5DE4FBQ36811505-F6126A6A-05A2-418E-94CB-CAAD3070F168Q37050094-8CD5E46D-D3BE-4DE9-89E7-F98E83CE84CBQ37403279-0E626302-0EF9-42CB-B0CA-2D2968F4F102Q37413649-1B53FBDA-B1A6-44D8-A87F-8FAA690FC38EQ37730116-9E7229E8-32AD-414F-BC1B-E3CEECEE824AQ37777745-899066FF-95BE-42B5-895B-DB9DD5AE9B41Q38051738-B4E5DFDC-9DC5-4641-9263-2B6769D7C0AEQ41191391-30F9CC58-7FA6-407B-A73E-171F37191169Q50071368-2826F392-0EEB-424A-A931-A2BC59FAF6D2
P2860
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Turning the gene tap off; impl ...... ssion for cancer therapeutics.
@en
type
label
Turning the gene tap off; impl ...... ssion for cancer therapeutics.
@en
prefLabel
Turning the gene tap off; impl ...... ssion for cancer therapeutics.
@en
P2093
P2860
P1476
Turning the gene tap off; impl ...... ssion for cancer therapeutics.
@en
P2093
James F Curtin
Maria G Castro
Marianela Candolfi
Pedro R Lowenstein
Weidong Xiong
P2860
P304
P356
10.1158/1535-7163.MCT-07-2328
P577
2008-03-01T00:00:00Z